Administration of Linoleoylethanolamide Reduced Weight Gain, Dyslipidemia, and Inflammation Associated with High-Fat-Diet-Induced Obesity

Acylethanolamides (NAEs) are bioactive lipids derived from diet fatty acids that modulate important homeostatic functions, including appetite, fatty acid synthesis, mitochondrial respiration, inflammation, and nociception. Among the naturally circulating NAEs, the pharmacology of those derived from either arachidonic acid (Anandamide), oleic acid (OEA), and palmitic acid (PEA) have been extensively characterized in diet-induced obesity. For the present work, we extended those studies to linoleoylethanolamide (LEA), one of the most abundant NAEs found not only in plasma and body tissues but also in foods such as cereals. In our initial study, circulating concentrations of LEA were found to be elevated in overweight humans (body mass index (BMI, Kg/m2) > 25) recruited from a representative population from the south of Spain, together with AEA and the endocannabinoid 2-Arachidonoyl glycerol (2-AG). In this population, LEA concentrations correlated with the circulating levels of cholesterol and triglycerides. In order to gain insight into the pharmacology of LEA, we administered it for 14 days (10 mg/kg i.p. daily) to obese male Sprague Dawley rats receiving a cafeteria diet or a standard chow diet for 12 consecutive weeks. LEA treatment resulted in weight loss and a reduction in circulating triglycerides, cholesterol, and inflammatory markers such as Il-6 and Tnf-alpha. In addition, LEA reduced plasma transaminases and enhanced acetyl-CoA-oxidase (Acox) and Uncoupling protein-2 (Ucp2) expression in the liver of the HFD-fed animals. Although the liver steatosis induced by the HFD was not reversed by LEA, the overall data suggest that LEA contributes to the homeostatic signals set in place in response to diet-induced obesity, potentially contributing with OEA to improve lipid metabolism after high fat intake. The anti-inflammatory response associated with its administration suggests its potential for use as a nutrient supplement in non-alcoholic steatohepatitis

Best practices in hospitality and tourism marketing and management : a quality of life perspective

xi, 369 p. ; 26 cm

Chronology of the Middle Palaeolithic open-air site of Combe Brune 2 (Dordogne, France): a multi luminescence dating approach

International audienc

Palmitoleoylethanolamide is an efficient anti-obesity endogenous compound: Comparison with oleylethanolamide in diet-induced obesity

Obesity is currently a major epidemic in the developed world. However, we lack a wide range of effective pharmacological treatments and therapies against obesity, and those approved are not devoid of adverse effects. Dietary components such as palmitoleic acid have been proposed to improve metabolic disbalance in obesity, although the mechanisms involved are not well understood. Both palmitoleic acid (POA) and oleic acid (OA) can be transformed in N-acylethanolamines (NAEs), mediating the effects of dietary POA and OA. To test this hypothesis, here, we study the effects on food intake and body weight gain of palmitoleylethanolamide (POEA) and the OA-derived NAE analogue, oleoylethanolamide (OEA), in Sprague–Dawley rats with a hypercaloric cafeteria diet (HFD). Plasma biochemical metabolites, inflammatory mediators, and lipogenesis-associated liver protein expression were also measured. The results indicate that POEA is able to improve health status in diet-induced obesity, decreasing weight, liver steatosis, inflammation, and dyslipemia. The action of POEA was found to be almost identical to that of OEA, which is an activator of the nuclear peroxisome proliferator receptor alpha (PPARα), and it is structurally related to POEA. These results suggest that the dietary administration of either POA or POEA might be considered as nutritional intervention as complementary treatment for complicated obesity in humans

MANMADE. Diseñando los puestos de trabajo a la medida de las personas

[ES] Los trabajadores deben ser entendidos como el elemento esencial en el entorno de una fábrica. Desde esta perspectiva, se tendrá que adaptar el lugar de trabajo y la planificación de la producción a las habilidades, conocimientos y características de cada trabajador, para aprovechar al máximo el conocimiento y el potencial de los trabajadores en todos los grupos de edad y en diferentes funciones, fomentando simultáneamente una mayor seguridad en sus puestos de trabajo. Sobre esta base, el proyecto "MANufacturing through ergonoMic and Safe Antrophocentric aDaptive workplaces for context aware factoires in EUROPE. MANMADE" promueve la implantación de nuevos modelos de puestos de trabajo adecuados a los trabajadores en términos de accesibilidad, inclusividad, eficiencia y satisfacción laboral. Este planteamiento proporciona un mayor rendimiento del trabajador y, en consecuencia, una mayor competitividad empresarial.Este proyecto ha recibido financiación del Séptimo Programa Marco de Investigación, desarrollo tecnológico y demostración de la Unión Europea a través del contrato nº 609073.Castelló Mercé, P.; Sánchez Palop, L.; Sanchís Almenara, M.; Solaz Sanahuja, JS.; Laparra Hernandez, J.; Ferreras Remesal, A.; Signes Pérez, E.... (2017). MANMADE. Diseñando los puestos de trabajo a la medida de las personas. Revista de Biomecánica (Online). (64). http://hdl.handle.net/10251/104214S6